NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS

COMPANY PRESENTATION

March 2022

ASX:NSB

NeuroScientific BIOPHARMACEUTICALS

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

COMPANY HIGHLIGHTS

DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTIC DRUGS

Developing peptide-based drugs with disease modifying potential for neurodegenerative conditions

EMTINB™: LEAD DRUG CANDIDATE WITH DISEASE MODIFYING POTENTIAL

A first-in-class treatment for Alzheimer's disease, Multiple sclerosis and glaucoma

TRANSITIONING FROM PRECLINICAL TO CLINICAL DEVELOPMENT IN 1H CY2022

EmtinB™ is set to enter a first-in-human Phase I clinical trial in the first half of 2022

COMPANY OVERVIEW

CAPITAL STRUCTURE

ASX CODE	**NSB**
SHARE PRICE (23/04/22)	**$0.29**
SHARES ON ISSUE	**143.5M**
UNLISTED OPTIONS	**16.8M**
MARKET CAPITALISATION	**$42M**
NET CASH POSITION	**$9.5M**
TOP 20 SHAREHOLDERS	**48%**

SHARE PRICE CHART

BOARD & MANAGEMENT

PAUL RENNIE	MATT LIDDELOW	DR ANTON UVAROV	STEPHEN QUANTRILL
CHAIRMAN	CEO & MANAGING DIRECTOR	EXECUTIVE DIRECTOR	NON-EXECUTIVE DIRECTOR
Founder of Paradigm (ASX:PAR) Former COO of Mesoblast (ASX:MSB)	Experienced pharma executive 14+ years industry experience	Founding Director of Actinogen (ASX:ACW) Former equities analyst with Citigroup, US	20+ years corporate advisory Executive Chairman of McRae Investments

ADDRESSING GLOBAL UNMET MEDICAL NEED IN NEURODEGENERATIVE CONDITIONS

The underlying cause of most neurodegenerative conditions is not known

ALZHEIMER'S DISEASE

40M PATIENTS WORLDWIDE

MOST SEVERE TYPE OF DEMENTIA

NO DISEASE MODIFING DRUGS AVAILABLE

MULTIPLE SCLEROSIS

$27B MARKET VALUE

AGE OF ONSET 20-50Y

NO EFFECTIVE DRUGS TO TREAT LATER-STAGE OF DISEASE

OPTIC NEUROPATHIES

70M INCIDENCE OF GLAUCOMA

2nd LEADING CAUSE OF BLINDNESS

CURRENT TREATMENT OPTIONS NOT SUITABLE FOR ALL PATIENTS

DEVELOPING A SOLUTION IS CHALLENGING WHEN THE CAUSE IS NOT FULLY UNDERSTOOD

NSB'S RESEARCH IS A POTENTIAL SOLUTION BY HARNESSING THE BODY'S DEFENSE MECHANISMS TO COMBAT NEURODEGENERATIVE DISEASES

EMTINB™: LEAD DRUG CANDIDATE WITH DISEASE MODIFYING POTENTIAL

EmtinB™ promotes cell survival and regeneration, and reduces inflammation in neurodegenerative conditions

EMTINB™



- Advanced peptide structure, synthetically manufactured
- Low potential for off-target effects – highly specific for target receptor
- Crosses the blood brain barrier

MODELLED ON HUMAN PROTECTIVE PROTEIN MT-II



- Large body of published data demonstrating protective and regenerative activity
- Commercialisation of MT-II limited by complex structure, not able to be synthetically manufactured

EMTINB™ TARGETS LRP-1

- LRP-1 receptor is expressed by most cells of the nervous system
- EmtinB activates LRP-1 pathways that stimulate cell survival, induce regeneration, and downregulate inflammation

EMTINB™ DISEASE MODIFYING EFFECT IN ALZHEIMER'S DISEASE

ALZHEIMER'S DISEASE – PREVENTING COGNITIVE DECLINE



- Validated in the gold-standard animal model
- Protected tissue of the brain and improved memory
- Reduced inflammation

EMTINB™ DISEASE MODIFYING EFFECT IN MULTIPLE SCLEROSIS

MULTIPLE SCLEROSIS – POTENTIAL TO TREAT ALL STAGES





- Increased the number of myelin-forming cells (oligodendrocytes)
- Increased myelin production
- Increased survival and regeneration of neurons

Recently announced data demonstrated a significant downregulation of the inflammatory responses of immune cells strongly associated with Multiple Sclerosis

NeuroScientific
BIOPHARMACEUTICALS

EMTINB™ DISEASE MODIFYING EFFECT IN GLAUCOMA

GLAUCOMA – PROTECTING THE OPTIC NERVE AND PREVENTING VISION LOSS





- Performed in pig model; structure of the eye very similar to humans
- Prevented damage to retinal cells
- Prevented damage to the optic nerve

EMTINB™ – DEVELOPMENT PIPELINE



NeuroScientific
BIOPHARMACEUTICALS

PARTNERING WITH LEADING RESEARCH ORGANISATIONS

NON-CLINICAL RESEARCH

labcorp Drug Development

Biospective

mdbiosciences. Neuroscience Discovery Services

imeka

neuron experts

eurofins

BioAgilytix

Lions Eye Institute

CLINICAL RESEARCH

linear

AGILEX BIOLABS

imeka

TRANSITIONING TO CLINICAL DEVELOPMENT

NSB is progressing EmtinB™ to Phase I clinical trials in 1H CY2022

EmtinB™ — **FIRST-IN-HUMAN PHASE I STUDY**

DISCOVERY RESEARCH

Basic validation of drug candidate

PRECLINICAL TOXICOLOGY

GLP safety and toxicology studies in animals



PHASE I CLINICAL TRIAL

Assessment of safety in healthy human subjects

PHASE II CLINICAL TRIAL

Assessment of safety and efficacy in patients



PHASE III CLINICAL TRIAL

Assessment of efficacy and safety in large patient groups

REGULATORY REVIEW & APPROVAL

Assessment of safety and efficacy in patients

NeuroScientific BIOPHARMACEUTICALS

MORE INFORMATION TO BE PROVIDED IN UPCOMING ANNOUNCEMENTS (ASX:NSB)

CONTACT INFORMATION

For more information:

Matt Liddelow
CEO & Managing Director

E: ml@neuroscientific.com

www.neuroscientific.com

NeuroScientific
BIOPHARMACEUTICALS